South Africa Lung Cancer Therapeutics Market Report 2022 to 2030

South Africa Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the South Africa Lung Cancer Therapeutics Market will reach a value of $396 Mn from $194 Mn in 2022, growing at a CAGR of 9.3% during 2022-2030. The Lung Cancer Therapeutics Market in South Africa is dominated by a few domestic pharmaceutical companies such as Akacia Medical, Adcock Ingram, and Aspen Pharmacare. The Lung Cancer Therapeutics Market in South Africa is segmented into different types of cancer and different therapy type. Some of the major factors affecting the South African lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.

ID: IN10ZAPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: South Africa AUTHOR: Dr. Vishwa Modhia

Buy Now

South Africa Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the South Africa Lung Cancer Therapeutics market will reach a value of $396 Mn from $194 Mn in 2022, growing at a CAGR of 9.3% during 2022-2030.

South Africa is an upper-middle-income, developing country located at the southern tip of the African continent. South Africa's healthcare system is organised into public (83%) and private (17%) sectors. The majority of basic primary health care is given in rural areas. Patients with lung cancer are referred to a tertiary care facility for treatment. The public health care system is understaffed and under-resourced. South Africa has no official lung cancer screening programmes. Non-profit organisations such as the Cancer Association of South Africa help to fund cancer research and educate the public about symptoms, early identification, screening, and risk reduction. South Africa has fewer than 40 medical oncologists.

Most of them are located in Gauteng Province. In South Africa, advanced thoracic surgery, specialist systemic treatments, particular pathological evaluation, and enhanced radiotherapy procedures for lung carcinomas are available, albeit mostly in the private sector. According to the latest WHO data published in 2020 Lung Cancers Deaths in South Africa reached 7,705 or 1.7% of total deaths. The age-adjusted Death Rate is 18.34 per 100,000 population ranks South Africa 64^th in the world. South Africa's government spends 4.6% of its GDP on healthcare.

South Africa Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

South Africa has a long tradition of providing high-quality thoracic surgical care, which was pioneered in the 1970s by the late Andrew Logan and Benjamin le Roux. Thoracic surgery has grown since that time and is currently available in all nine provinces. Most surgical procedures are conducted in Gauteng, the Western Cape, the Free State, Kwazulu Natal, and the Eastern Cape. South Africa has access to all chemotherapeutic drugs for SCLC and NSCLC. In public hospitals, only low-cost generic chemotherapies are accessible. These aspects could boost the South Africa Lung Cancer Therapeutics market.

Market Restraints

South Africa is divided into nine provinces, and the incidence of lung cancer and treatment choices vary by region. The National Cancer Registry was founded in 1986 to give statistics on cancer incidence in South Africa. It is a pathology-based system that was most recently modified in 2014. Lung cancer is most likely underreported in South Africa. Patients in the public sector frequently have advanced diseases. Lack of education, restricted access, and delayed referrals are all possible causes. Pemetrexed is not covered by most provinces for non-squamous NSCLC. In the public sector, specialised medications such as targeted therapy, such as bevacizumab, are not available.

New therapies must go through a lengthy registration process, which might take up to 5 years in some situations. Compassionate use programmes occasionally make new agents available. The country has roughly 83 teletherapy units. Only three of the country's nine provinces have more than 64 (77%) of these. These factors may deter new entrants into the South Africa Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Aspen Pharmacare: Aspen Pharmacare is a South African pharmaceutical company that specializes in the production and distribution of generic medicines. The company offers a range of cancer treatments including chemotherapy drugs
Adcock Ingram: Adcock Ingram is a South African pharmaceutical company that specializes in the production and distribution of over-the-counter and prescription medicines. The company offers a range of cancer treatments including chemotherapy drugs
Akacia Medical: Akacia Medical is a South African company that specializes in the production and distribution of generic medicines. The company offers a range of cancer treatments including chemotherapy drugs
Be-Tabs Pharmaceuticals: Be-Tabs Pharmaceuticals is a South African company that specializes in the production and distribution of generic medicines. The company offers a range of cancer treatments including chemotherapy drugs
Cipla Medpro: Cipla Medpro is a South African company that specializes in the production and distribution of generic medicines

Healthcare Policies and Reimbursement Scenarios

The South African Health Items Regulatory Authority (SAHPRA) is responsible for the approval and regulation of therapeutic products, especially lung cancer therapies, in South Africa. SAHPRA took over the functions of the Medicines Control Council (MCC) and the Directorate of Radiation Control (DRC), both of which were situated under the National Department of Health (NDoH). In the private sector, access to pricey new agents is limited since most medical funders reject them from their programmes. Funders who do fund these therapies make them available only to patients on their highest tiers (approximately 20%).

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.